Short Interest in BlackRock Health Sciences Trust (NYSE:BME) Declines By 56.0%

BlackRock Health Sciences Trust (NYSE:BME) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 6,200 shares, a decline of 56.0% from the November 15th total of 14,100 shares. Based on an average daily volume of 38,100 shares, the short-interest ratio is presently 0.2 days.

BlackRock Health Sciences Trust Trading Up 0.2 %

NYSE:BME opened at $38.68 on Friday. The company’s 50-day moving average is $40.31 and its two-hundred day moving average is $40.84. BlackRock Health Sciences Trust has a 1-year low of $38.00 and a 1-year high of $42.86.

BlackRock Health Sciences Trust Dividend Announcement

The firm also recently disclosed a monthly dividend, which will be paid on Monday, December 23rd. Investors of record on Monday, December 16th will be issued a $0.2621 dividend. This represents a $3.15 dividend on an annualized basis and a yield of 8.13%. The ex-dividend date is Monday, December 16th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BME. Raymond James Trust N.A. lifted its stake in shares of BlackRock Health Sciences Trust by 8.1% in the 2nd quarter. Raymond James Trust N.A. now owns 22,036 shares of the company’s stock valued at $900,000 after purchasing an additional 1,649 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in BlackRock Health Sciences Trust by 4.3% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 54,605 shares of the company’s stock worth $2,231,000 after buying an additional 2,240 shares during the period. Calamos Advisors LLC increased its position in shares of BlackRock Health Sciences Trust by 46.4% during the second quarter. Calamos Advisors LLC now owns 7,884 shares of the company’s stock valued at $322,000 after acquiring an additional 2,500 shares during the last quarter. Consolidated Portfolio Review Corp increased its position in shares of BlackRock Health Sciences Trust by 7.2% during the third quarter. Consolidated Portfolio Review Corp now owns 42,574 shares of the company’s stock valued at $1,785,000 after acquiring an additional 2,853 shares during the last quarter. Finally, Raymond James & Associates raised its stake in shares of BlackRock Health Sciences Trust by 7.0% in the 2nd quarter. Raymond James & Associates now owns 44,877 shares of the company’s stock valued at $1,833,000 after acquiring an additional 2,931 shares during the period.

BlackRock Health Sciences Trust Company Profile

BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services.